IP Library Granted Patent US 7,892,835
Granted Patent B2
US 7,892,835 · App. 10/593,831 · Granted Feb 22, 2011

Pluripotent stem cell growing method

Assignee: Daiichi Sankyo Company, Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,892,835
App. No.
10/593,831
Granted
Feb 22, 2011
Kind
B2
Abstract

A novel growing method is provided for pluripotent stem cells such as ES cells. The method of the invention is a pluripotent stem cell growing method and gene transfer method in which pluripotent stem cells are cultured under conditions that maintain their undifferentiated state and pluripotency, the method being characterized by using a liquid medium and a culturing vessel having immobilized or coated on a substrate solid phase surface a molecule which is adhesive to the pluripotent stem cells in a fixed concentration, to grow the pluripotent stem cells in a dispersed state while maintaining their undifferentiated state and pluripotency, without using feeder cells, or to transfer and express a gene therein.

Claims (13)

1. A method for growing pluripotent stem cells which exhibit a normal karyotype comprising contacting said pluripotent stem cells with a liquid medium and growing said pluripotent stem cells in said liquid medium in a dispersed state in a culturing vessel without using feeder cells, wherein said pluripotent stem cells maintain their undifferentiated state and pluripotency, said culturing vessel including immobilized or coated on a substrate solid phase surface a cadherin molecule, and wherein said pluripotent stem cells achieve cell counts at least two times greater than said pluripotent stem cells cultured on a gelatin plate after four days.

2. The method of claim 1 , further comprising transferring a gene into said pluripotent stem cells, after culturing.

3. The method of claim 1 , wherein said cadherin molecule is E-cadherin, or a molecule which has structural homology with said molecule, which comprises the EC1 domain and one or more domains from among the EC2 domain, EC3 domain, EC4 domain and EC5 domain of E-cadherin, and which has homophilic binding ability with said pluripotent stem cells.

4. The method of claim 3 , wherein said E-cadherin is mammalian.

5. The method of claim 4 , wherein said E-cadherin is human or mouse.

6. The method of claim 1 , wherein said cadherin molecule is fused with an immunoglobulin Fc region and is immobilized on said substrate solid phase surface via said Fc region.

7. The method of claim 1 , wherein said pluripotent stem cells are mammalian embryonic stem cells (ES cells) or embryonic germ cells (EG cells).

8. The method of claim 2 , wherein said cadherin molecule is E-cadherin, or a molecule which has structure homology with said molecule, which comprises the EC1 domain and one or more domains from the EC2 domain, EC3 domain, EC4 domain and EC5 domain of E-cadherin, and which has homophilic binding ability with said pluripotent stem cells.

9. The method of claim 8 , wherein said E-cadherin is mammalian.

10. The method of claim 9 , wherein said E-cadherin is human or mouse.

11. The method of claim 2 , wherein said cadherin molecule is fused with an immunoglobulin Fc region and is immobilized on said substrate solid phase surface via said Fc region.

12. The method of claim 2 , wherein said pluripotent stem cells are mammalian embryonic stem cells (ES cells) or embryonic germ cells (EG cells).

13. The method of claim 2 , wherein said cadherin molecule is a human or a mouse E-cadherin and said pluripotent stem cells are mammalian embryonic stem cells (ES cells).

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2016
From: DAIICHI SANKYO COMPANY, LIMITED; FUKUDA, KEIICHI
To: AKAIKE, TOSHIHIRO
Reel/Frame 039985/0606 →
CHANGE OF NAME Recorded Aug 11, 2010
From: ASUBIO PHARMA CO. LTD.
To: DAIICHI SANKYO COMPANY, LIMITED
Reel/Frame 024820/0927 →
CHANGE OF NAME Recorded Apr 25, 2007
From: DAIICHI ASUBIO PHARMA CO., LTD.
To: ASUBIO PHARMA CO. LTD.
Reel/Frame 019231/0621 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2006
From: AKAIKE, TOSHIHIRO; FUKUDA, KEIICHI; NAGAOKA, MASATO; KOSHIMIZU, UICHI
To: AKAIKE, TOSHIHIRO; FUKUDA, KEIICHI; DAIICHI ASUBIO PHARMA CO., LTD.
Reel/Frame 018356/0136 →
Priority Claims (1)
JP 2004-085393 · Mar 23, 2004 · national
Continuity (1)
Related Publication 20070155013A1 · Jul 5, 2007